NC 318
Alternative Names: NC-318Latest Information Update: 09 May 2024
At a glance
- Originator Yale University School of Medicine
- Developer Emory University; Merck Sharp & Dohme; National Cancer Institute (USA); NextCure; Yale University School of Medicine
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Leukaemia; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 09 May 2024 NC 318 is available for licensing as of 08 May 2024. https://www.sec.gov/ix?doc=/Archives/edgar/data/1661059/000155837024003672/nxtc-20231231x10k.htm
- 12 Sep 2023 Efficacy and adverse event data from phase II trial in Non-small cell lung cancer released by NextCure
- 09 Sep 2023 Updated Efficacy data from a phase II trial in Non-small cell lung cancer presented at the 24th World Conference on Lung Cancer, 2023 (WCLC-2023)